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DISTURBANCE IN HEMOGLOBIN METABOLISM AND in vivo ANTIMALARIAL 
ACTIVITY OF AZOLE ANTIMYCOTICS
Juan Ricardo RODRIGUES, Diana LOURENCO & Neira GAMBOA
SUMMARY
Plasmodium parasites degrade host hemoglobin to obtain free amino acids, essential for protein synthesis. During this event, free 
toxic heme moieties crystallize spontaneously to produce a non-toxic pigment called hemozoin or ß-hematin. In this context, a group 
of azole antimycotics, clotrimazole (CTZ), ketoconazole (KTZ) and fluconazole (FCZ), were investigated for their abilities to inhibit 
ß-hematin synthesis (IßHS) and hemoglobin proteolysis (IHbP) in vitro. The ß-hematin synthesis was recorded by spectrophotometry 
at 405 nm and the hemoglobin proteolysis was determined by SDS-PAGE 12.5%, followed by densitometric analysis. Compounds 
were also assayed in vivo in a malaria murine model. CTZ and KTZ exhibited the maximal effects inhibiting both biochemical events, 
showing inhibition of β-hematin synthesis (IC50 values of 12.4 ± 0.9 µM and 14.4 ± 1.4 µM respectively) and inhibition of hemoglobin 
proteolysis (80.1 ± 2.0% and 55.3 ± 3.6%, respectively). There is a broad correlation to the in vivo results, especially CTZ, which 
reduced the parasitemia (%P) of infected-mice at 4th day post-infection significantly compared to non-treated controls (12.4 ± 3.0% 
compared to 26.6 ± 3.7%, p = 0.014) and prolonged the survival days post-infection. The results indicated that the inhibition of the 
hemoglobin metabolism by the azole antimycotics could be responsible for their antimalarial effect.
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INTRODUCTION
Malaria remains one of the major infectious diseases in tropical 
countries and the emergence of resistance to the main antimalarial drugs 
along with the absence of a successful vaccine have led to a bigger risk 
of death in those areas11. Therefore, there is a compelling and urgent 
necessity for the discovery of new antimalarials13.
Hemoglobin degradation in intraerythrocytic malaria parasites is a 
biochemical event which occurs in the parasite acidic digestive vacuole 
by different proteases to provide free amino acids necessary for protein 
synthesis10. In this process, the oxidant heme group is separated from the 
globin chains and the parasite is protected from the deleterious effects of 
this porphyrin by its crystallization into an insoluble non-toxic pigment 
called hemozoin or ß-hematin4. 
Azole antifungals clotrimazole (CTZ) and ketoconazole (KTZ) seem 
to act by preventing the synthesis of this pigment, an effect which is shared 
by quinoline compounds12. Moreover, CTZ has exhibited antimalarial 
activity in cultures of P. falciparum18. In this context we have evaluated 
the ability of the azole antimycotics, CTZ, KTZ and fluconazole (FCZ) to 
inhibit ß-hematin synthesis and globin proteolysis in vitro together with 
the evaluation of their effects on a Plasmodium berghei-murine model.
MATERIAL AND METHODS
Reagents: CTZ, KTZ and FCZ (Fig. 1) were a generous gift given 
by Calox de Venezuela C.A. For in vitro assays, drugs were prepared 
as 100mM stock solution. CTZ and FCZ were dissolved in ethanol 
while KTZ was dissolved in methanol. All of the stock solutions were 
stored at 4 °C. These solutions were diluted before the assays to reach 
final concentrations. For in vivo experiments, the dissolved azole 
compounds were diluted in Saline-Tween 20 (2%) and adjusted to a final 
concentration of 20 mg/kg/mouse. 
Fig. 1 - Azole antimycotic structures. CTZ: clotrimazole; KTZ: ketoconazole; FCZ: 
fluconazole.
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Inhibition of ß-hematin synthesis: The inhibition of ß-hematin 
synthesis assay was performed according to a previous procedure3. In 
short, a solution of hemin chloride in DMSO (50 mL, 5.2 mg/mL) was 
distributed in 96-well micro plates. Different concentrations of dissolved 
compounds in DMSO (100-5 mM) were added in triplicate in test wells 
(50 mL) at final concentrations between 25 and 0.25 mM. Controls contained 
water (50 mL), DMSO (50 mL) or chloroquine (50 mL, 25-0.25 mM). The 
β-hematin synthesis was initiated by the addition of acetate buffer (100 mL, 
0.2M, pH 4.4). Plates were incubated at 37 ºC for 48 h to allow completion 
of the reaction and centrifuged (20000 g x 15 min). After discarding the 
supernatant, the pellet was washed three times with DMSO (200 mL), 
dissolved in NaOH (200 mL, 0.2N) and diluted 1:2 with NaOH (0.1N), 
recording the absorbances at 405 nm (Microplate Reader, BIORAD-550). 
The obtained results were expressed as percentage of inhibition of 
ß-hematin synthesis relative to the drug-free control.
Experimental host and strain maintenance: Male albino mice 
(BALB/c, 18-22 g, were maintained on a commercial pellet diet and 
housed under conditions approved of by the Ethics Committee, School 
of Pharmacy, Central University of Venezuela. Plasmodium berghei 
(ANKA strain), a rodent malarial parasite, was used for infection. Mice 
were infected intraperitoneally with 107 infected erythrocytes diluted 
in phosphate buffer saline solution (PBS 10 mM, pH 7.4, 0.1 mL). 
Parasitemias were monitored by microscopic examination of Giemsa 
stained smears.
Mice native hemoglobin: Native hemoglobin from non-infected 
mice was obtained by mixing one volume of pellet erythrocytes and two 
volumes of water. The resulting lysate was used as the substrate in the 
hemoglobin proteolysis assay. 
Parasite extracts: Blood of infected animals with high levels 
of parasitemia (30-50%) was collected via cardiac puncture. After 
centrifugation (500g x 10 min, 4 ºC), plasma and buffy coat were 
removed, and the red blood cells (RBCs) pellet was washed twice with 
chilled PBS-glucose (5.4%). The washed RBCs were centrifuged on a 
discontinuous percoll gradient (80-70% percoll in PBS-Glucose, 20000 g 
x 30 min, 4 ºC). The resulted upper band (erythrocytes infected with the 
mature forms of the parasites) was removed by aspiration, and washed 
twice with chilled PBS-glucose and lysed with saponin (0.1% in PBS 
x 10min). After adding cold PBS (1 mL) the samples were centrifuged 
(13000 g x 5 min, 4 ºC) to remove erythrocyte cytoplasmic material. Free 
parasites were suspended in PBS-glucose (5.4%) and subjected to three 
freeze-thaw cycles (-70 ºC / + 37 ºC) to obtain the final parasite extract 
which was used for the hemoglobin proteolysis assay17.
Hemoglobin proteolysis assay: The proteolytic effect of the parasite 
extract on the mouse hemoglobin was assayed using 96-well tissue 
culture plate. The assay mixture contained: mouse native hemoglobin 
(10 mL), parasite extract (50 mL), GSH (10 mL, 10 mM) and buffer acetate 
(0.2M, pH 5.4) to a final volume of 200 mL. The dissolved compounds 
(10 mL) were incorporated into the incubation mixture (5 µM final 
concentration). The incubations were carried out at 37 ºC for 18 hours and 
the reaction was stopped by addition of buffer (Tris base 0.125M, SDS 2%, 
ß-mercaptoethanol 5%, glycerol 20%, Bromophenol Blue 0.0025 %). The 
degree of digestion was evaluated electrophoretically by SDS-PAGE-15%17 
followed by densitometric analysis of intact globin bands. Results were 
expressed as percentage of inhibition of hemoglobin proteolysis.
Four-day suppressive test (Peters´ test): Azole antimycotics were 
also evaluated in a malaria murine model by the four-day suppressive 
test15 using chloroquine as a positive control (20 mg/kg). In short, native 
BALB/c mice (18-23 g) were infected intraperitoneally (ip) with 107 
parasitized RBCs on day 0. Antimycotics were freshly prepared, dissolved 
in DMSO (0.1 M) and diluted with Saline-Tween 20 solution (2%). Two 
hours after the infection, mice received the first treatment (20 mg/kg, 
ip) and then every 24 hours for four consecutive days. Blood smears 
from the tails were prepared on the fourth day and parasitemias were 
determined by microscopic examination of Giemsa-stained blood films. 
Survivals were followed up until day 30th post-infection. The results were 
expressed as percentage of parasitemia on the fourth day post-infection 
and as survival days post-infection.
Data were presented as the average of four independent experiments 
(n = 4) and tested for statistical significance using unpaired t-tests for 
specific group comparisons assuming 95% confidence limits using 
GraphPad Prism 4.02 software. The maintenance of the experimental 
animals complied with the guidelines of the human use of laboratory 
animals. 
RESULTS
Quinoline antimalarials as chloroquine are well known to inhibit 
β-hematin synthesis. In this study we confirmed that CTZ and KTZ 
exhibited a marked inhibition of β-hematin production. Special 
attention was paid to CTZ which reported no difference compared to 
positive control of chloroquine at the maximal dose tested (Table 1). 
On the other hand, the compounds alone (control without hemin) did 
not absorb at the same wavelength of β-hematin absorption (405 nm), 
which showed that the results represented a positive inhibition of this 
biochemical event.
Additionally, the study of the intact hemoglobin bands by 
electrophoretic analysis indicated that CTZ, KTZ and FCZ inhibited 
globin proteolysis (intact band at 14.4 kDa). CQ-treatment of trophozoites 
cultured with hemoglobin partially inhibited globin proteolysis (Fig. 2).
Moreover, the densitometric analysis showed more than 50% of 
inhibition of globin proteolysis for each of the azole compounds tested. 
These structures were more than twice as active as CQ (Fig. 3). This 
evidence supports a possible new mechanism of antimalarial action of 
these antimycotic compounds whereby parasites are deprived of the 
amino acids required for protein synthesis.
Table 1 
Inhibition of β-hematin synthesis (IβHS) by azole antimycotics 
COMPOUND %IβHS IC50(µM)
Clotrimazole 80.2 ± 0.9 † 12.4 ± 0.9
Ketoconazole 68.9 ± 1.4 14.4 ± 1.4
Fluconazole < 5 > 50
Chloroquine 80.5 ± 3.0 0.41 ± 0.13
The results are expressed as the mean ± SEM at the maximal dose tested (100 µM) 
and half maximal inhibitory concentration (IC50). †p > 0.05 compared to chlo-
roquine. (n = 4). 
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The in vivo results demonstrated that CTZ and KTZ were able to 
reduce the parasitemia levels at 4th day post-infection with significant 
differences compared to non treated infected animals (Fig. 4a). 
CTZ-treated mice also showed a prolongation of their survival rates; 
however, this drug did not clear the infection at the tested dose (Fig. 4b). 
Parasitemias of CQ-treated mice were cleared at the end of the assay and 
no deaths were registered in this group of animals. In this context, it is 
possible that the effects we observed in vivo could be correlated to the 
inhibition of β -hematin formation and globin proteolysis.
DISCUSSION
Plasmodium parasites degrade host hemoglobin through their aspartic 
and cysteine proteases as a source of nutrients8. In this process, free toxic 
heme moieties crystallize spontaneously in the acid environment of the 
digestive vacuole to an insoluble pigment called hemozoin or ß-hematin14. 
Chloroquine has been shown to inhibit hemozoin formation6 and this 
process is also thought to be the molecular target of other quinoline 
antimalarials19. Moreover the bisquinoline compound dequalinium 
has demonstrated antimalarial activity also through the inhibition of 
the globin proteolytic degradation16. Thus, ß-hematin synthesis and 
hemoglobin proteolysis, unique events occurring within the malaria 
parasites, offer a logical and valuable potential target for the development 
of new antimalarials.
TIFFERT et al.18 showed that CTZ inhibits P. falciparum growth in 
vitro, alters its morphology and interferes with parasite development and 
replication. Moreover, a series of heterocyclic azole-based compounds 
were described as inhibitors of P. falciparum lactate dehydrogenase 
at micromolar concentrations and these compounds displayed modest 
activity against parasitized erythrocytes, including parasite strains with 
known resistance to existing antimalarials and against Plasmodium 
berghei in BALB/c mice7.
Mechanisms of the antimalarial activity of CTZ have been proposed 
in relation to Ca2+ ions. This drug inhibits the sarcoplasmic reticulum 
Ca+2 pump, causing the depletion of intracellular Ca2+ stores5,18. This 
effect produces the activation of protein kinase R and phosphorylation 
of eukaryotic translation initiation factor 2α, which in consequence, 
inhibits protein synthesis1. However, the effects of CTZ and other azolic 
antifungal compounds on the hemoglobin proteolysis in malaria parasites 
are not known.
Our results confirmed that the imidazole compounds CTZ and KTZ 
inhibit ß-hematin formation, which might be due to the ability of these 
structures to form complexes with free heme moieties as it has been 
demonstrated with other antimalarials8. CHONG & SULLIVAN8 showed 
that these compounds also inhibited this event; however, we reported 
a stronger inhibition by CTZ compared to KTZ. Indeed, HUY et al.12 
observed that the hydrophobic group of CTZ, three aromatic rings with a 
chlorine atom, should stabilize axial ligation to heme and forms a stable 
Fig. 2 - Effects of azole antimycotics on globin proteolysis. Standard Molecular Weight (MW) 
is expressed in kilo Daltons (14.4 kDa). A: undegraded globin (control hemoglobin without 
trophozoites of P. berghei); B: control hemoglobin with trophozoites; CTZ: hemoglobin with 
trophozoites and clotrimazole (5 µM). KTZ: ketoconazole (5 µM); FCZ: fluconazole (5 µM); 
LEP: leupeptin (cysteine protease inhibitor); PEP: pepstatin (aspartic protease inhibitor); CQ: 
chloroquine; MeOH: control methanol; EtOH: control ethanol.
Fig. 3 - Percentage of inhibition of the hemoglobin proteolysis by azole antimycotics 
(%IHbP). The results are expressed as the mean ± SEM. Azole compounds were assayed at 
5 µM. Leupeptin: cysteine protease inhibitor; Pepstatin: aspartic protease inhibitor. (n = 4).
Fig. 4 - In vivo antimalarial activity of azole antimycotics. a) Percentage of parasitemia at 4th 
day post-infection; b) SDPI: survival days post-infection. CTZ: clotrimazole (20 mg/kg); KTZ: 
ketoconazole (20 mg/kg); FCZ: fluconazole (20 mg/kg); CQ: chloroquine (20 mg/kg). The 
results are expressed as the mean ± SEM. *p < 0.05 and **p < 0.01 compared to non-treated 
infected mice (saline solution, SS) n = 6.
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six-coordinate iron porphyrin complex with a high equilibrium association 
constant, which could explain the strong effects of this drug inhibiting 
the β-hematin formation in our results. When the amount of heme-CTZ 
complexes becomes critical, malaria-infected erythrocytes are expected to 
be hemolyzed, leading to parasite death. On the other hand, FCZ did not 
show activity inhibiting ß-hematin synthesis. This compound has a triazolic 
structure and it is possible that three nitrogen atoms are not favorable for 
the complex formation with free heme. Moreover, in this study we did not 
observe 100% of inhibition at the maximal dose tested and this could be 
due to the saturation of the compounds in the biological system.
These azole compounds were also tested for inhibition of globin 
proteolysis. The electrophoretic analysis indicated that the antimycotics 
were effective as inhibitors of hemoglobin degradation. Special attention 
should be paid to CTZ, which demonstrated the strongest effect inhibiting 
this event. Therefore, azole compounds exhibited activity avoiding 
free amino acid production by P. berghei from host hemoglobin. The 
mechanism of action of these drugs seems to be directly dependent 
on cysteine and/or aspartic protease inhibition since these proteases 
can degrade native globin during the initial steps of the hemoglobin 
degradation and leupeptin and pepstatin (cysteine and aspartic protease 
inhibitors) also inhibit this event10. The antimycotics were not tested as 
falcipain or plasmepsin inhibitors in vitro; however, the mechanism of 
action of these compounds on hemoglobin degradation could be related 
to the inhibition of one or both proteases. In this context, it would be 
necessary to examine the effect of the compounds on plasmepsin and 
cysteine proteases directly in further investigations.
GEMMA et al.9 previously described the in vivo antimalarial activity 
of CTZ orally by the decrease of the parasitemia levels in treated animals. 
In this context, we confirmed the activity of this compound and also 
KTZ in a malaria murine model. Both compounds were able to reduce 
the parasitemias at 4th day post-infection and CTZ increased the survival 
rate with significant differences compared to non-treated infected mice. 
These results could be the consequence of a dual mechanism of action, 
correlating the in vivo activity with the inhibition of ß-hematin formation 
and the inhibition of hemoglobin proteolysis. KTZ was also described to 
be active in vivo in a multidrug resistant Plasmodium yoelii nigeriensis 
murine model at high doses and enhanced the protective effect of 
mefloquine against the infection2. 
It is important to note that the in vivo antimalarial activity of CQ is 
much stronger than that of the azole compounds and this could be due to 
dosage or bioavailability factors. It would therefore be interesting to assay 
different dose regimens or to develop some water soluble derivatives, 
which may provide a new medicinal chemistry route for research into 
this infectious disease. It would be important to test these compounds 
against chloroquine-resistant strains to determine their true value as 
antimalarials.
In conclusion, we propose that azole antimycotics, especially CTZ 
and KTZ could show antimalarial properties by the inhibition of two 
biochemical events occurring in the malaria parasite: the β-hematin 
synthesis and the globin proteolysis; the last one representing an 
alternative and new mechanism of action against the malaria parasites 
by these structures. Further enhancement of these structures might yield 
candidates suitable for consideration as new therapeutic compounds for 
the treatment of malaria. 
RESUMEN
Alteración en el metabolismo de la hemoglobina y actividad 
antimalárica in vivo de azoles antimicóticos
Los parásitos del género Plasmodium degradan la hemoglobina 
hospedera obteniendo aminoácidos libres para su síntesis proteica. 
Durante este evento, unidades de hemo libre tóxicas cristalizan 
espontáneamente formando un pigmento no tóxico denominado 
ß-hematina. En este trabajo, se investigó la capacidad de un grupo de 
azoles antimicóticos: clotrimazol (CTZ), ketoconazol (KTZ) y fluconazol 
(FCZ), en inhibir la síntesis de ß-hematina y la proteólisis de la globina. 
La síntesis de ß-hematina se registro por espectrofotometría a 405 nm y la 
proteólisis de la hemoglobina se determino por SDS-PAGE 15% seguido 
por análisis densitométrico de las bandas de hemoglobina intactas. Los 
compuestos fueron también ensayados in vivo en un modelo de malaria 
murina. CTZ y KTZ inhibieron la síntesis de ß-hematina con CI50 entre 10 
y 15 µM y bloquearon la proteólisis de la hemoglobina (80.01 ± 2.04% y 
55.33 ± 3.57%, respectivamente). En relación directa con los resultados 
encontrados in vitro, el CTZ redujo la parasitemia de ratones infectados 
en forma significativa, así como prolongó lo días de sobrevivencia 
post-infección en comparación con animales controles no tratados. Se 
sugiere así que la inhibición del metabolismo de la hemoglobina por 
los antimicóticos azólicos pudiera ser el mecanismo responsable de su 
actividad antimalárica.
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